Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Maps Out China Strategy

This article was originally published in PharmAsia News

Executive Summary

Last year, even as the worldwide pharmaceutical market growth slowed down to 3.8 percent, China powered ahead with a 15 percent increase. Eli Lilly's Chairman and CEO, Sidney Taurel, revealed that the company's business in China grew by 28 percent, which greatly fueled the overall corporate global performance. China Lilly is shifting its strategy from a FIPCO (Fully Integrated Pharmaceutical Company) model to FIPNET (Fully Integrated Pharmaceutical Network) model, which emphasizes collaboration rather than acquisition. The MNC has pumped investment into its China office as well as three local enterprises in Shanghai. Lilly China is exploring opportunities in community hospitals and will participate in drug tenders called by such organizations. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068088

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel